Oct 20, 2026 06:59AM
Sep 30, 2026 09:09AM
Aug 13, 2026 02:45AM
Aug 12, 2026 06:20AM
Aug 6, 2026 04:16PM
Aug 6, 2026 08:04AM
Jul 21, 2026 03:46AM Citizens Starts Annexon Biosciences (ANNX) at Market Underperform
Jul 20, 2026 06:50AM
Jul 15, 2026 07:28AM
Jul 13, 2026 07:39AM
May 12, 2026 05:15AM
May 7, 2026 06:40PM
Apr 13, 2026 05:52AM
Mar 31, 2026 05:27PM Jefferies on Annexon Biosciences (ANNX): APLS deal shows 'big pharma interested in complement space'
Mar 31, 2026 06:16AM
Mar 31, 2026 06:14AM
Mar 20, 2026 06:47AM
Mar 19, 2026 07:34AM
Jan 14, 2026 06:57AM
Jan 12, 2026 07:08AM
Dec 23, 2025 04:41AM Chardan Capital Markets Starts Annexon Biosciences (ANNX) at Buy
Dec 1, 2025 04:17PM
Aug 14, 2025 05:45PM
Aug 7, 2025 04:31PM
May 19, 2025 04:07PM
May 13, 2025 07:55AM
May 13, 2025 06:19AM
Mar 5, 2025 06:45AM Annexon Biosciences (ANNX) PT Lowered to $20 at H.C. Wainwright
Mar 3, 2025 04:26PM
Jan 13, 2025 08:13AM
Dec 17, 2024 06:53AM
Dec 17, 2024 04:43AM
Dec 16, 2024 07:31AM
Oct 23, 2024 07:49AM
Oct 15, 2024 08:02AM Annexon (ANNX) to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
Oct 1, 2024 06:45AM
Aug 13, 2024 09:28AM
Aug 13, 2024 06:20AM
Aug 12, 2024 08:40AM
Aug 6, 2024 09:24AM
Jun 26, 2024 09:18AM
Jun 25, 2024 05:00PM Annexon (ANNX) Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome
Apr 5, 2024 07:00PM

471,077 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All